An Update on the Etiopathogenesis of NAFLD including Organokines for Early Diagnosis and Improvement of Management and Preventing Early HCC Development: A Narrative Review
DOI:
https://doi.org/10.17140/lroj-4-115Keywords:
Non-alcoholic fatty acid liver disease (NAFLD), Organokines, Oxidative stress, Inflammation, DyslipidemiaAbstract
Background
Earlier, we reviewed different methods of treating non-alcoholic fatty acid liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), concentrated on organokines liberated by adipose tissue (AT) and liver (adipoklines and hepatokines), adipokines in obesity with heart failure (HF), and myokines like irisin in exercise in obesity, and thought they might work as diagnostic and therapeutic targets in NAFLD and NASH with hepatocellular carcinoma (HCC). These are believed to be biological markers that can anticipate the robustness of NAFLD from NAFLD to HCC.
Methods
We conducted a narrative review utilizing search engines PubMed, Google Scholar; Web of Science; Embasee; Cochrane Library utilizing the MeSH terms “NAFLD”; “NASH”; “Organokines”; “Adipokines”; “Hepatokines”; “Myokines”; “Osteokines”; “Stellakines”; “Fructose”; “Gut Microbiota”; “Insulin resistance (IR)”; “Crosstalk of organokines”; “Obesity”; “T2D” from last 10-years till date in 2023.
Results
We found a total of 750 articles, out of which we selected 95 for this review. No meta-analysis has been done.
Conclusion
As acknowledged earlier, NAFLD possesses the characteristics of simple steatosis, while NASH progresses to hepatic steatosis, lobular inflammation, and an escalated diameter of hepatocytes (ballooning of hepatocytes) with or without fibrosis in 20% of cases of NAFLD. Usually, it is correlated with metabolic diseases like obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome (MetS); hence, the liberation of organokines gets manipulated in a way that might aid in the etiopathogenesis or propagation of disease. We observed that insulin resistance (IR), oxidative stress (OS), mitochondrial impairment, fructose, and gut microbiota reflected factors taking part in the development and propagation of NASH. Alterations in various organokines (in clusive of adipokines, hepatokines, myokines, osteokines, and a newer one, stellakines) produced by hepatic stellate cells (HSCs) were further seen to directly or indirectly aid in the exacerbation and propagation of disease or cause dysfunctional homeostasis. Moreover, we discuss the role of stellakines in detail, and targeting silymarin might give us an efficacious drug for the early treatment of NAFLD or NASH.
References
Gariani K, Jornayvaz FR. Pathophysiology of NASH in endo-crine diseases. Endocr Connect. 2021; 10: R52-R65. doi: 10.1530/ EC-20-0490
Ayada I, Van KleefLA, Alferink LJM, LiP, De Knight RJ, Pan Q. Systematically epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the nonoverlap groups. Liver Int. 2021; 42: 277-287. doi: 10.1111/liv.15139
Tilg H, Eiffenberger M. From NAFLD to MAFLD: When pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020; 17: 387-388. doi: 10.1038/s41575-020-0316-6
Eslam M, Sanyal AJ, George J, Sanyal A; International Consen-sus Panel. MAFLD: A Consensus driven proposed nomenclature for metabolic fatty liver disease. Gastroenterology. 2020; 158: 1999- 2014.e1. doi: 10.1053/j.gastro.2019.11.312
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction – associated fatty liver disease. J Hepatol. 2020; 73: 202-209. doi: 10.1016/j.jhep.2020.03.039
De A, Ahmad N, Mehta M, Singh P, Duseja A. NAFLD vs MAFLD – it is not the name but the disease that decides the out-Systematic Review | Volume 4 | Number 1 | come of fatty liver. J Hepatol. 2021; 76: 475-477. doi: 10.1016/j. jhep.2021.09.002
Day CP, James OF. Steatohepapititis: A tale of two hits? Gastro-enterology. 1998; 114: 842-845. doi: 10.1016/s0016-5085(98)70599-2
Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: Current concepts and future challeng-es. Nat Rev Gastroenterol Hepatol. 2019; 16: 411-28. doi: 10.1038/ s41575-019-0145-7
Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advanc-es in the involvement of gut microbiota in pathophysiology of NAFLD. Front Med. 2020; 7: 361. doi: 10.3389/fmed.2020.00361
Lonardi A, Mantovani A, Lugari S, Targher S. Epidemiology and pathophysiology of the association between metabolically healthy or metabolically unhealthy Obesity. Ann Hepatol. 2020; 19: 359-366. doi: 10.1016/j.aohep.2020.03.001
Margiotti dos Santos JF, DeMailoMC, Lemes MA, et al. Non-alcoholic steatohepapititis (NASH) and organokines: What is now and what will be in the future. Int J Mol Sci. 2022; 23: 498. doi: 10.3390/ijms23010498
Sheka AC, Adeyi O, Thompson J, Hameed B, Cawford PA, Ikramuddin S. Non-alcoholic steatohepapititis: A review. JAMA. 2020; 323: 1175-1183. doi: 10.1001/jama.2020.2298
DiStefano JK. NAFLD and NASH in post menopausal wom-en: implications for diagnosis and treatment. Endocrinology. 2020; 161: bqaa134. doi: 10.1210/endocr/bqaa134
Kim H, Lee DS, An TH, et al. Metabolic spectrum of Liver-failure in type 2 Diabetes and obesity: From NAFLD to NASH to HCC. Int J Mol Sci. 2021; 22: 4495. doi: 10.3390/ijms22094495
Kaur KK, Allahbadia GN. Therapeutic applications of the recent understanding of brown or beige adipocyte physiology. Adv Tech Biol Med. 2015; 3: 128. doi: 10.4172/2379-1764.1000128
Kaur KK, Allahbadia GN, Singh M. Advances in BAT physi-ology for understanding and translating into pharmacotherapies for obesity and comorbidities. MOJ Drug Des Develop Ther. 2018; 2(5): 166-176. doi: 10.15406/mojddt.2018.02.00057
Kaur KK, Allahbadia GN, Singh M. Weight loss associated with high protein diet intake in obesity: Interactions of gut mi-crobiota in protein sources influencing this positive effect. Acta Scientific Nutritional Health. 2018; 2(7): 80-89.
Kaur KK, Allahbadia GN, Singh M. A mini review on de-velopment of newer therapies for non-alcoholic fatty acid liver disease with emphasis on vitamin D and its receptor and allyl iso-thiocyanate (AITC). Acta Scientific Nutritional Health. 2019; 3(12): 1-5.
Kaur KK, Allahbadia GN, Singh M. An update on further Systematic Review | Volume 4 | Number 1 | Kaur KK, et al progression of NAFLD, NASH with prospective therapies like L-Carnitine (LC), Nicotinamide Ribose (NR) combination, as well as apical sodium dependent bile acids transporter (ASBT) or volixibat and silybin as alternatives. Int J Clin Med Cases. 2020; 3(3): 138. doi: 10.31021/ijcmc.20203138-29/1/2020
Kaur KK, Allahbadia GN, Singh M. Have probiotics and syn-biotics passed the test of time to be implemented in manage-ment of obesity and related metabolic disorders-a comprehen-sive review. Adv Obes Weight Manag Control. 2019; 9(1): 21-28. doi: 10.15406/aowmc.2019.09.00269
Kaur KK, Allahbadia GN, Singh M. Will probiotics pro-vide the answer for therapy of non-alcoholic fatty liver disease (NAFLD)? – a systematic review. Biochem Physiol. 2020; 9: 257.
Kaur KK, Allahbadia GN, Singh M. Are we any close to unraveling the mechanism of interactions among susceptibility genes towards type 1 diabetes, gut microbiota along with envi-ronmental factors, specifically early diet patterns – a systematic review. J Endocrinology and Surgical Endocrinology. 2021; 2(1): 1-20.
Kaur KK, Allahbadia GN, Singh M. How do we apply ad-vances in knowledge of hepatic macrophages in treating liver dis-eases especially non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepapititis (NASH), with the increasing incidence of diabesity-a systematic review. EC Endocrinology and Metabolic Research. 2021.
Kaur KK, Allahbadia GN, Singh M. Mechanisms that associ-ate extension of Nonalcoholic fatty liver diseases (NAFLD) to NASH (Non-alcoholic steatohepatitis) and further progressing to cirrhosis and Hepatocellular carcinoma (HCC) in addition to few proposed biomarkers for poor prognosis. J Gynaecol. 2021; 1(16): 1-18.
Kaur KK, Allahbadia GN, Singh M. How can we optimize therapy of non-alcoholic fatty acid liver disease-a short commu-nication on role of astragaloside IV and other prospective agents. Clinical Research and Clinical Case Reports. 2021; 1(3): 1-4.
Kaur KK, Allahbadia GN, Singh M. Intestinal immune system in the regulation of obesity and metabolic syndrome-therapeu-tic implications-a systematic review. EC Clinical and Experimental Anatomy. 2020; 3(7): 7-22.
Kaur KK, Allahbadia GN, Singh M. An update on manage-ment of non-alcoholic fatty liver disease & nonalcoholic steato-hepapititis-is the time ripe for achieving resolution of NAFLD & NASH soon. J Endocrinol Res. 2021; 3(2): 44-60. doi: 10.30564/ jer.v3i2.3580
Kaur KK, Allahbadia GN, Singh M. The Association of non viral liver diseases from NAFLD to NASH to HCC with the pan-demic of obesity, type 2 diabetes, or diabesity & metabolic syn-drome – etiopathogenetic correlation along with utilization for diagnostic & therapeutic purposes-a systematic review. J Endocri-nol Res. 2021; 3(2): 10-34. doi: 10.30564/jer.v3i2.3520
Kaur KK. Advantages and limitations of utilizing clostridium species as probiotics-a sytematic review. Paper presented at: In a webinar held by Gastroenterology Conference; September 30, 2020. Punjab, India. https://www.longdom.org/open-access-pdfs/advantages-and-limitations-of-utilizing-clostridium-spe-cies-as-probioticsasytematic-review.pdf. Accessed December 15, 2022.
Kaur KK, Allahbadia GN, Singh M. The association of di-etary fatty acids and gut microbiota alterations in the develop-ment of neuropsychiatric diseases: A systematic review. Obes Res Open J. 2020; 7(1): 19-45. doi: 10.17140/OROJ-7-143
Kaur KK, Allahbadia GN, Singh M. Role of adipocyte im-pairment in heart failure induction in subjects that are obese along with prediabetes and overt diabetes mellitus - a systematic review. Int J Cardiol & Card. 2021; 2(2): 1-21.
Kaur KK, Allahbadia GN, Singh M. An update on the asso-ciation of gut-liver axis with gut microbiome dysbiosis correlated NAFLD along with NAFLD- HCC with potential therapeutic ap-proaches: A systematic review. J Hepatol Gastroenterol. 2022; 8: 216. doi: 10.35248/2475-3181.22.8.216
Armandi A, Rosso C, Caviglia GP, Bglanesi E. Insulin resis-tance across the spectrum of non-alcoholic fatty liver disease. Me-tabolites. 2021; 11: 155. doi: 10.3390/metabo11030155
Attia SL, Softic S, Mouzaki M. Evolving role for pharmaco-therapy in NAFLD/NASH. Clin Transl Sci. 2021; 14: 11-19. doi: 10.1111/cts.12839
Xiao X, Hu Q, Deng X, et al. Old wine in new bottles: Kaem-pherol is a promising agent for treating triology of liver diseases. Pharmacol Res. 2021; 175: 106005. doi: 10.1016/j.phrs.2021.106005
Longo M, Paolini M, Meroni M, Dongiovanni P. Remod-elingof mitochondrial plasticity: The key switch from NAFLD to NASH to HCC. Int J Mol Sci. 2021; 22: 4173. doi: 10.3390/ ijms22084173
Pierantonelli I, Svegliati-Baroni G. Non-alcoholic fatty liv-er disease: Basic pathogenetic mechanism in the progression from NAFLD to NASH. Transplantation. 2019; 103: e1-e13. doi: 10.1097/TP.0000000000002480
Softic S, Meyer JG, Wang GX, et al. Dietarysugars after he-patic fatty acids oxidation via transcriptional and posttranscrip-tional modificationsof mitochondrial proteins. Cell Metab. 2019; 30: 735-754.e4. doi: 10.1016/j.cmet.2019.09.003
Dong J, Viswanathan S, Adami E, et al. Hepatocyte specific IL11 cissignaling drives lipotoxicity and underlies the transition from NAFLD to NASH. Nat Commun. 2021; 12: 66. doi: 10.1038/ s41467-020-20303-z
Jensen T, Abdelmalek MF, Sullivan S, et al. Fructoseand sugar: A major mediator of non-alcoholic steatohepapititis. J Hepatol. 2018; 68(5): 1063-1075. doi: 10.1016/j.jhep.2018.01.019
Jegatheesan P, De Bandt JP. Fructose and NAFLD: The mul-tifaceted aspects of fructose metabolism. Nutrients. 2017; 9: 230. doi: 10.3390/nu9030230
DiStefano JK. Fructose mediatedeffects on gene expression and epigenetic mechanisms associated with NAFLD pathogen-esis. Cell Mol Life Sci. 2020; 77(11): 2079-2090. doi: 10.1007/ s00018-019-03390-0
Muriel P, Lopez- Sanchez P, Ramos-Tovar E. Fructose and the liver. Int J Mol Sci. 2021; 22: 6969. doi: 10.3390/ijms22136969
Chan AML, Ng AMH, Yunus MHM, et al. Recent develop-ment in rodent models of high fructose diet-induced metabolic syndrome: A systematic review. Nutrients. 2021; 13: 2497. doi: 10.3390/nu13082497
Eshraghian A, Nikeghbalian S, Geramizadeh B, Kazemi K, Shamsaeefar A, Malek-Hosseini SA. Characterization of biopsy proven non-alcoholic fatty liver diseasein healthy non obese and lean population of living liver donors: The impact of uric acid. Clin Res Hepatol Gastroenterol. 2020; 44: 572-578. doi: 10.1016/j. clinre.2019.09.002
Cui Y, Liu J, Shi H, Hu W, Song L, Zhao O. Serum uric acid is positively associated with the prevalence of Non-alcoholic fatty liver in non obese type 2 Diabetic patients in Chinese popula-tions. J Diabetes Complications. 2021; 35: 107874. doi: 10.1016/j. jdiacomp.2021.107874
Frederico A, Rosato V, Masarone M, et al. The role of fruc-tose in non-alcoholic steatohepapititis: Old relationship and new insights. Nutrients. 2021; 13: 1314. doi: 10.3390/nu13041314
Perez-Montes de OcaA, Julian MT, Ramos A, Puig Domingo M, Alonso N. Microbiota, fiber and NASH: Is there any connec-tion? Nutrients. 2020; 12: 3100. doi: 10.3390/nu12103100
Vasques-Monteiro IML, Silva-Veiga FM, Miranda CS, de Andrade Gonçalves ECB, Daleprane JB, Souza-Mello V. A rise in Proteobacteria is an indicator of gut-liver axis mediated non-alcoholic fatty liver diseasein high-fructose-fed adult mice. Nutr Res. 2021; 91: 26-35. doi: 10.1016/j.nutres.2021.04.008
Semmler G, Datz C, Reiberger T, Trauner M. Diet and exer-cise in NAFLD/NASH: Beyond the obvious. Liver Int. 2021; 41: 2249-2268. doi: 10.1111/liv.15024
Marusic M, Palc M, Knobloch M, Liberati PraoA-M. NAFLD, insulin resistance and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021; 2021: 6613827. doi: 10.1155/2021/6613827
Loomba R,Morgan E,Watts L,Xia S,Hannan LA,Geary RS, et al. Novel antisense inhibition of Diacyl glycerol- acetyl trans-ferase for treatment of non-alcoholic fatty liver disease: A mul-ticenter, double blinded, randomized placebo-controlled parallel, Systematic Review | Volume 4 | Number 1 | phase 2 Clinical trial. Lancet Gastroenterol Hepatol. 2020; 5: 829-38. doi: 10.1016/S2468-1253(20)30186-2
Kirk B, Feehan J, Lombardi G, Duque G. Muscle, bone and fatcrosstalk: The biological role of myokines, osteokines and adi-pokines. Curr Osteoporosis Res. 2020; 18: 388-400. doi: 10.1007/ s11914-020-00599-y
Kukukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines myokines in NASH related Hepa-tocellular carcinoma. J Hepatol. 2021; 74: 442-57. doi: 10.1016/j. jhep.2020.10.030
Choi KM. The impact of organokineson insulin resistance, inflammation and atherosclerosis. Endocrinol Metab. 2016; 31: 1-6. doi: 10.3803/EnM.2016.31.1.1
Petta S, Gestaldelli A, Rebelos A, et al. Pathophysiology of non-alcoholic fatty liver disease: Multiple interactions. Int J Mol Sci. 2016; 17: 2082. doi: 10.3390/ijms17122082
De Oliveira Mar Santodos Santos AR, De Oliveira Zanuso B, Miola VFB, et al. Adipokines, myokines and hepatokines: Cross-talk and repercussions. Int J Mol Sci. 2021; 22: 2639. doi: 10.3390/ ijms22052639
Panera N, Corte CD, Crudele A, Stronati L, Nobili V, Alisi A. Recent advances in understanding the role of adipocytokines dur-ing non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert Rev Gastroenterol Hepatol. 2016; 10: 393- 403. doi: 10.1586/17474124.2016.1110485
Marques V, Afonso MB, Bierig N, et al. Adiponectin, leptin and IGF1are useful diagnostic and stratification biomarkers of NAFLD. Front Med (Lausanne). 2021; 8: 683250. doi: 10.3389/ fmed.2021.683250
Polyzos SA, Kountouras J, Anastasilakis AD. Irisin in non-alcoholic fatty liver disease: Need for updated meta-analysis. Me-tabolism. 2021; 121: 154818. doi: 10.1016/j.metabol.2021.154818
Zorena K, Jachimowicz-Duda O, Slezak D, Rabakowska M, Mrugacz M. Adipokines and obesity: Potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020; 21: 3570. doi: 10.3390/ijms21103570
Han D, Chen L, Liu S, et al. Serum resistin levelsin adult pa-tientswith non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Clin Transl Hepatol. 2021; 9: 484-493. doi: 10.14218/JCTH.2021.00018
Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK. Resis-tin: A journey from metabolism to cancer. Transl Oncol. 2021; 14: 101178. doi: 10.1016/j.tranon.2021.101178
Polyzos SA, Kountouras J, Anastasilakis AD, Geldari EV, Mantzoros CS. Irisin in patients with non-alcoholic fatty liver disease. Metabolism. 2014; 63: 207-217. doi: 10.1016/j.metab-Systematic Review | Volume 4 | Number 1 | Kaur KK, et al ol.2013.09.013
Ke Y, Xu C, Lin J, Li Y. Role of hepatokines in non-alcoholic fatty liver disease. J Transl Int Med. 2019; 7: 143-148. doi: 10.2478/ jtim-2019-0029
Diaz BB, Gonzalez DA, Gannar F, Perez MCR, De Leon AC. Myokines, physical activity, insulin resistance and autoim-mune diseases. Immunol Lett. 2018; 203: 1-5. doi: 10.1016/j.im-let.2018.09.002
Gonzalez-Gil AM, Elizando-Mmontemayor L.The role of ex-ercise in the interplay between myokines, hepatokines, osteokines and adipokines and modulation of inflammation for energy sub-strate redistribution and fat mass loss. Nutrients. 2020; 12: 1899. doi: 10.3390/nu12061899
Lebensztejn DM, Flisiak-Jackiwicz M, Bialokoz-Kalinowska J, Bobrus-Chociej A, Kowalska I. Hepatokines and non-alco-holic fatty liver disease. Acta Biochem Pol. 2016; 63: 459-67. doi: 10.18388/abp.2016_1252
Berja-Fernandez S, Folguiera C, Castelao C, et al. ANGPTL-4 is associated with obesity and lipid profile in children and adoles-cents. Nutrients. 2019; 11: 1340. doi: 10.3390/nu11061340
Takata N, Ishii K, Takayama H, et al. LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macro-phagesin NASH. Sci Rep. 2021; 11: 555. doi: 10.1038/s41598-020- 80689-0
Saez-Lopez C,SalcedoAllendeMT, Hernandez C,Simo Servat O, Simo R,Selva DM. Sex hormone binding globulin expression correlates with acetyl-coenzyme A carboxylase and triglyceride content in the liver. J Clin Endocrinol Metab. 2019; 104: 1500-1507. doi: 10.1210/jc.2018-00740
Chen M-J, Ho H-N. Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016; 37: 119-128. doi: 10.1016/j.bpobgyn.2016.03.003
Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharm Sci. 2015; 36: 461-470. doi: 10.1016/j.tips.2015.04.014
Baboota RK, Bluher M, Smith U. Emerging role of bone mor-phogenetic protein-4 in metabolic disorders. Diabetes. 2021; 70: 303-312. doi: 10.2337/db20-0884
Colaianni G, Storlino G, Sanesi L, Colucci S, Grano M. Myo-kines and osteokines in the pathogenesis of muscle and bone diseases. Curr Osteoporosis Rep. 2020; 18: 401-407. doi: 10.1007/ s11914-020-00600-8
Cobbina E, Akhlagi E. Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification and effects on metaboliz-ing enzymes and transporters. Drug Metab Rev. 2017; 49: 197-211. doi: 10.1080/03602532.2017.1293683
Ezquerro S, Mocha F, Fruhbeck G, et al. Ghrelin reduceshu-man hepatocytes apoptosis,autophagy, and pyroptosis: Role in obesity associated NAFLD. J Clin Endocrinol Metab. 2019; 104: 21- 37. doi: 10.1210/jc.2018-01171
Yang L, Roh YS, Song J, et al. Transforming growth fac-tor beta signaling in hepatocytes participatesin steatohepapititis through regulationof cell death and lipid metabolism in mice. Hepatology. 2014; 59: 483-95. doi: 10.1002/hep.26698
Barbalho SM, Flato UAP, Tofar RJ, et al. Physical exercise and myokines: Relationship with sarcopenia and cardiovascu-lar complications. Int J Mol Sci. 2020; 21: 3607. doi: 10.3390/ ijms21103607
Xie C, Chen Q. Adipokines: New therapeutic targets for Osteoarthritis. Curr Rheumatol Rep. 2019; 21: 71. doi: 10.1007/ s11926-019-0868-z
An X, Liu J, Li Y, et al. Chemerin/CMKLR1 ameliorated non-alcoholic steatohepapititis by promoting autophagy and al-leviating oxidative stress through JAK2/STAT 3 pathway. Peptides. 2021; 135: 170422. doi: 10.1016/j.peptides.2020.170422
Ye D, Yang K, Zang S, et al. Lipocalin 2 mediates non-al-coholic steatohepapititis by promoting neutrophils macrophages crosstalk via the induction of CXCR2. J Hepatol. 2016; 65: 988- 997. doi: 10.1016/j.jhep.2016.05.041
Moschen AR, Adolph TE, Gerner RR, Weiser V, Tilg H. Li-pocalin 2: Amaster mediator of intestinal and metabolic inflam-mation. Trends Endocrinol Metab. 2017; 28: 388-397. doi: 10.1016/j. tem.2017.01.003
Mazzolini G, Atorrasagasti C, Onorato A, et al. SPARC ex-pression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. Sci Rep. 2018; 8: 725. doi: 10.1038/s41598-017-18981-9
Onorato AM, Fiore E, Bayo J, et al. SPARC inhibition accel-erates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipids metabolism. Liver Int. 2021; 41: 1677-1643. doi: 10.1111/liv.14857
Flisiak JackiwiczM, Bobrus Chociej A,WasilewskaN,Tarasow E,Wotjowska M, Lebensztejn DM. Can hepatokines be regarded as non invasive serum biomarkers of intra hepatic lipid content in obese children? Adv Med Sci. 2019; 64: 280-284. doi: 10.1016/j. advms.2019.02.005
Shojaie L, Iorga A, Dara L. Cell death in liver diseases: A re-view. Int J Mol Sci. 2020; 21(24): 9682. doi: 10.3390/ijms21249682
Xiong X, Kuang K, Ansari S, et al. Landscape of intercel-lular crosstalk in healthy and NASH liver revealed bysingle-cell secretome gene analysis. Mol Cell. 2019; 75(3): 644-660.e5. doi: 10.1016/j.molcel.2019.07.028
Chang E-J, Lee SK, Song YS, et al. IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin En-docrinol Metab. 2014; 99(7): E1268- E1271. doi: 10.1210/jc.2013-
Mohallem R, Aryal UK. Regulators of TNF: Mediatedinsu-lin resistance elucidated by quantitative proteomics. Sci Rep. 2020; 10(1): 20878. doi: 10.1038/s41598-020-77914-1
Sun S-C. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017; 17(9): 545-58. doi: 10.1038/ nri.2017.52
Jin J, Hu H, Li HS, et al. Noncanonical NF-κB pathway con-trols the production of type I interferons in antiviral innate im-munity. Immunity. 2014; 40(3): 342-354. doi: 10.1038/nri.2017.52
Konishi T, Schuster RM, Goetzman HS, Caldwell CC, Lentsch AB. Fibrotic liver has prompt recovery afterischemia-reperfusion injury. Am J Physiol Gastroenterol Liver Physiol. 2020; 318(3): G390- G400. doi: 10.1152/ajpgi.00137.2019
Hong L, Shejiao D, Fenrong C, Gang Z, Lei D. Periostin down-regulation attenuates the pro-fibrogenic response of he-patic stellate cells induced by TGF-β. J Cell Mol Med. 2015; 19(10): 2462-2468. doi: 10.1111/jcmm.12636
Prakoura N, Kavvadas P, Kormann R, Dussaule JC, Chadji-christos CE, Chatziantoniou C. NF-κB-induced periostin activates integrin-β3 signaling to promote renal injury in GN. J Am Soc Nephrol. 2017; 28(5): 1475-1490. doi: 10.1681/ASN.2016070709
Izuhara K, Nunomura S, Nanri Y, et al. Periostin in inflam-mation and allergy. Cell Mol Life Sci. 2017; 74(23): 4293-4303. doi: 10.1007/s00018-017-2648-0
Chen JY, He XX, Ma C, et al. Netrin-1 promotes gliomagrowth by activating NF-κB via UNC5A. Sci Rep. 2017; 7(1): 5454 . doi: 10.1038/s41598-017-05707-0
Deng Y, Li J, Zhou M, Liang Z, Zhao L. c-Myc affects hedge-hog pathway via KCNQ1OT1/RAC1: A new mechanism for regulating HSC proliferation and epithelial-mesenchymal tran-sition. Dig Liver Dis. 2021; 11(14): 1458-1467. doi: 10.1016/j. dld.2020.11.035
Wang X, Liu Y, Zhang S, et al. Crosstalk between Akt and NF-κB pathway mediates inhibitory effect of gas6 onmonocytes-endothelial cells interactions stimulated byP. gingivalis-LPS. J Cell Mol Med. 2020; 24(14): 7979-7990. doi: 10.1111/jcmm.15430
Peng CK, Wu CP, Lin JY, et al. Gas6/Axl signalingattenu-ates alveolar inflammation in ischemia-reperfusioninduced acute lung injury by up-regulating SOCS3-mediated pathway. PLoS One. 2019: 14(7): e020219788. doi: 10.1371/journal.pone.0219788
Yu B, Chang J, Liu Y, et al. Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB. Nat Med. Systematic Review | Volume 4 | Number 1 | 2014; 20(9): 1009-1017. doi: 10.1038/nm.3586
Yin C, Ye Z, Wu J, et al. Elevated Wnt2 and Wnt4 activate NF-κB signaling to promote cardiac 7brosis by cooperation of Fzd4/2 and LRP6 following myocardial infarction. EBioMedicine. 2021; 74: 103745. doi: 10.1016/j.ebiom.2021.103745
Mizukami J, Takaesu G, Akatsuka H, et al. Receptor activa-torof NF- κB ligand (RANKL) activates TAK1 mitogenactivated protein kinase kinase kinase through a signaling complex contain-ing RANK, TAB2, and TRAF6. Mol Cell Biol. 2002; 22(4): 992- 1000. doi: 10.1128/MCB.22.4.992-1000.2002
Korbecki J, Kojder K, Kapczuk P, et al. The effect of hypox-ia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature. Int J Mol Sci. 2021; 22(2): 843. doi: 10.3390/ijms22020843
Warner KA, Miyazawa M, Cordeiro MM, et al. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia. 2008; 10(2): 131-139. doi: 10.1593/neo.07815
Strieter RM, Polverini PJ, Kunkel SL, et al. The function-al role of the ELR motif in CXC chemokine-mediated angio-genesis. J Biol Chem. 1995; 270(4): 27348-27357. doi: 10.1074/ jbc.270.45.27348
Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF κB-mediated upregulation of CXCR1 and CXCR2 expression pro-motes cell survival in hypoxic prostate cancer cells. Oncogene. 2007; 26(52): 733-745. doi: 10.1038/sj.onc.1210536
Sun Y, Xiong X, Wang X. RELA promotes hypoxiainduce-dangiogenesis in human umbilical vascular endothelial cells via LINC01693/miR-302d/CXCL12 axis. J Cell Biochem. 2019; 120(8); 12549-12558. doi: 10.1002/jcb.28521
Liu H, Li J, Tillman B, Morgan TR, French BA, French SW. TLR3/4 signaling is mediated via the NF κB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies. Exp Mol Patho. 2014; 97(2); 234-240. doi: 10.1016/j.yexmp.2014.07.001
Liang K, Liu Y, Eer D, Liu J, Yang F, Hu K. High CXC che-mokine ligand 16 (CXCL16) expression promotes proliferation and metastasis of lung cancer via regulating the NF-κB pathway. Med Sci Monitor. 2018; 24: 405-411. doi: 10.12659/msm.906230
Korbecki J, Kodjer K, Simi´nska D, et al. CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020; 21(21): 8412. doi: 10.3390/ijms21218412
Miyagaki T, Sugaya M, Murakami T, et al. CCL11-CCR3 in-teractions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation. Cancer Res. 2011; 71(6): 2056-2065. doi: 10.1158/0008-5472.CAN-10-3764 Systematic Review | Volume 4 | Number 1 | Kaur KK, et al
Park JY, Kang YW, Choi BY, Yang YC, Cho BP, ChoWG. CCL11 promotes angiogenic activity by activating the PI3K/Akt pathway in HUVECs. J ReceptorsSignal Transduction. 2017; 37(4): 416-421. doi: 10.1080/10799893.2017.1298132
Jin L, Liu WR, Tian MX, et al. CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget. 2017; 8(3): 5135-5148. doi: 10.18632/oncotarget.14095
Waddell A, Ahrens R, Tsai YT, et al. Intestinal CCL11 and eosinophilic in5ammation is regulated by myeloid cellspecific RelA/p65 in mice. J Immunol. 2013; 190(9): 604773-604785.
Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J. The NF-kappaB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-in5am-matory genes. J Hepatol. 2010; 53(3): 519-527. doi: 10.1016/j. jhep.2010.03.025
Makino Y, Hikita H, Kodama T, et al. CTGF mediatestumor-stroma interactions between hepatoma cells and hepatic stellate cells to accelerate HCC progression. Cancer Res. 2018; 78(17): 4902-4914. doi: 10.1158/0008-5472.CAN-17-3844
Chaqour B, Yang R, Sha Q. Mechanical stretch modulates the promoter activity of the profibrotic factor CCN2 through increased actin polymerization and NF-7B activation. J Biol Chem. 2006; 281(29): 20608-20622. doi: 10.1074/jbc.M600214200
Nagai N, Matoba K, Kawanami D, et al. ROCK2 regulat-esTGF-9-induced expression of CTGF and profibrotic genes via NF-7B and cytoskeleton dynamics in mesangial cells. Am J Physiol Renal Physiol. 2019; 317(4): F839-F851. doi: 10.1152/ajpre-nal.00596.2018
Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocel-lular carcinoma in non-alcoholic steatohepatitis: Current knowl-edge and implications for management. World J Hepatol. 2017; 9: 533-543. doi: 10.4254/wjh.v9.i11.533
Jing YY, Han Z, Sun K, et al. Toll like receptor 4 signal-ing promotes epithelial–mesenchymal transition in human Hepa-tocellular carcinoma induced by lipopolysaccharides. BMC Med. 2012; 10: 98. doi: 10.1186/1741-7015-10-98
Li H, Li Y, Liu D, Liu J. LPS promotes epithelial –mesenchy-mal transition and activation of TLR4/JNK signaling. Tumor Biol. 2014; 35: 10429-10435. doi: 10.1007/s13277-014-2347-5
Gupta H,Youn GS, Shin MJ, Suk KT. Gut microbiota in hepatocarcinogenesis. Microorganisms. 2019; 7: 121.
Saxena NK, Fu PP, Nagalingam A, et al. Adiponectin modu-lates c–jun N terminal kinase and mammalian target of rapamy-cin and inhibits hepatocellular carcinoma. Gastroenterology. 2010; 139: 1762-1773, 1773.e1-5. doi: 10.1053/j.gastro.2010.07.001
Al-Gayyar AM, Abbas A, Hamdan AM. Chemopreventive and hepatoprotective role of Adiponectin (SULF2 Inhibitor) in hepatocellular carcinoma. Biol Chem. 2016; 397: 257-267. doi: 10.1515/hsz-2015-0265
Kamada Y, Matsumoto H, Tamura S, et al. Hypo adipo-nectinemia accelerates hepatic tumorformation in non-alcoholic steatohepatitis mouse model. J Hepatol. 2007; 47: 556-564. doi: 10.1016/j.jhep.2007.03.020
Shen J, Yeh CC, Wang Q, et al. Plasma adiponectin and hepa-tocellular carcinoma survival among patients without liver trans-plantation. Anticancer Res. 2016; 36: 5307-5314. doi: 10.21873/ anticanres.11103
Stefanou N, Papanilkolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as acritical regulator of hepatocellular carci-noma development through modulation of human telomerase re-verse transcriptase. BMC Cancer. 2010; 10: 442. doi: 10.1186/1471- 2407-10-442
Wei R, Hu Y, Dong F, Xu X, Hu A, Gao G. Hepatoma cell-derived leptin down regulates the immunosuppressive function of regulatory T cells to enhance the anti tumor activity of CD 8+T cells. Immunol Cell Biol. 2016; 94: 388-399. doi: 10.1038/ icb.2015.110
Sliz E, Sebert S, Wurtz P, et al. NAFLD risk alleles in PNPLA2, TM5SF2, GCKR and LYPLAL1 show divergent meta-bolic effects. Hum Mol Genet. 2018; 27: 2214-2223. doi: 10.1093/ hmg/ddy124
Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brou-wers MCGJ. PNPLA3,TM6F2 and MBOAT17 genotypes and coronary artery disease. Gastroenterology. 2019; 152: 912-9123. doi: 10.1053/j.gastro.2016.12.020
Kaur KK, Allahbadia GN, Singh M. An update on the risk factors correlating NAFLD with cardiovascular disease: Specifi-cally mitochondrial - fatty acids β oxidation in liver with thera-peutic approaches of avoidance of CVD associated mortality-A systematic review. J Endocrinol. 2022; 6(1): 1-20. doi: 10.23880/ oaje-16000164
Kaur KK, Allahbadia GN, Singh M. Synergistic anti oxi-dant actions of mitochondrial palatin–like phospholipaseA2do-main–containing protein-8 (PNPLA8/iPLA2γ) with the fatty acids(FA)-translocating-SLC-25 gene family transporters with their sequelae-a review. Int J Med B Health Res. 2020; 4(1): 1-15.
Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug me-Submit your article to this journal | https://openventio.org/submit-manuscript/ tabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2): 197-211. doi: 10.1080/03602532.2017.1293683
Kaur KK, Allahbadia GN, Singh M. An update on mecha-nistic modes in AGEs stimulated & ER and inflammatory stress-modulated control of the GLUT4 expression (SLC2A4 pro-moted) and atherogenesis in diabetes mellitus-a narrative review. Mathews J Cytol Histol. 2022; 6(1): 21. doi: 10.30654/MJCH.10021
Zmora N, Suez J, Elinav E. You and what you eat: Diet, health and gut microbiota. Nat Rev Gastroenterol Hepatol. 2019; 16: 33-56. doi: 10.1038/s41575-018-0061-2
Janzi S, Gonzalez-Padilla E, Najafi K, et al. Single nucleotide polymorphisms in close proximity to the Fibroblast growth factor and 21 (FGF21) gene found to be associated with sugar intake in a Sweden population. Nutrients. 2021; 13: 3954. doi: 10.3390/ nu13113954
Safari Z, Gerard P. The links between the gut microbiome and Non-alcoholic fatty liver disease(NAFLD). Cell Mol Life Sci. 2019; 76: 1541-1558. doi: 10.1007/s00018-019-03011-w
Oh S, Tsujimoto T, Kim B, et al. Weight loss independent benefits of diet exercise on liver steatosis and stiffness in Japanese men with NAFLD. JHEP Rep. 2021; 3: 100253. doi: 10.1016/j. jhepr.2021.100253
Marjot T, Ray DW, Williams FR, Tomlinson JW, Armstrong MJ. Sleep and liver disease: A bidirectional relationship. Lancet Gastroenterol Hepatol. 2021; 6: 850-863. doi: 10.1016/S2468- 1253(21)00169-2
Staccchiotti A, Favero G, Rodella LF. Impact of melatonin on skeletal muscle and exercise. Cells. 2020; 9: 288. doi: 10.3390/ cells9020288
Yang B, Lu L, Zhou D, et al. Regulatory networks and in-terplay of hepatokines, stellakines, myokines adipokines, in non-alcoholic fatty liver diseases and non-alcoholic steatohepapititis. Front Endocrinol (Lausanne). 2022; 13: 1007944. doi: 10.3389/fen-do.2022.1007944
Vaccher M, Bansal S, Kumar B, et al. Contribution of orga-nokines in the development of NAFLD/NASH associated hepa-tocellular carcinoma. J Cell Biochem. 2022; 123(10): 1553-1584. doi: 10.1002/jcb.30252
Yang B, Yang X,TanX, et al. Regulatory networks, manage-ment approaches and emerging treatments for non-alcoholic fatty liver diseases. Can J Gastroenterol Hepatol. 2022; 2022: 6799414. doi: 10.1155/2022/6799414 Systematic Review | Volume 4 | Number 1 |
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.